CIAM
YMAB

Caitong International Asset Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Caitong International Asset Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-45
Closed -$352 – 2573
2024
Q4 		$352 Buy
+45
New +$548 ﹤0.01% 1512

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return

Caitong International Asset Management's YMAB Position: Q1 2025 in Review

Caitong International Asset Management sold out of Y-mAbs Therapeutics (YMAB) in Q1 2025, closing a stake of 45 shares — an estimated $352 sold.

Caitong International Asset Management first reported a position in YMAB in Q4 2024 and held it in 1 quarter. The position peaked at $352 in Q4 2024. 102 funds tracked by Wall St. Rank hold YMAB as of Q1 2025.

  • Caitong International Asset Management reported no remaining Y-mAbs Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Caitong International Asset Management sold 45 Y-mAbs Therapeutics shares in Q1 2025, an estimated $352.
  • Caitong International Asset Management first reported a position in Y-mAbs Therapeutics in Q4 2024 and held it in 1 quarter.
  • Caitong International Asset Management's Y-mAbs Therapeutics position peaked at $352 in Q4 2024.
  • 102 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2025.

Based on Caitong International Asset Management's 13F filing for Q1 2025, filed 13 May 2025.